摘要
目的探讨枯草杆菌肠球菌二联活菌胶囊对非酒精性脂肪性肝炎(NASH)患者肠道通透性及血清内毒素水平的影响。方法选择健康正常成人30例作为正常对照组和非酒精性脂肪性肝炎患者60例,给予后者枯草杆菌肠球菌二联活菌胶囊治疗4周。检测所有被研究者血清内毒素、二胺氧化酶(DAO)、D-乳酸及ALT水平。结果与对照组比较,治疗前患者内毒素、DAO、D-乳酸水平显著增高【分别为143.60±21.41EU/l对109.78±17.81EU/l(t=7.71,P<0.01);2.6±0.47U/ml对2.3±0.48U/ml(t=2.24,P<0.05);6.1±1.05mg/l对5.3±0.97mg/(l t=4.89,P<0.01)】;NASH患者治疗后与治疗前比较,内毒素、DAO、D-乳酸及ALT水平显著降低。结论非酒精性脂肪性肝炎患者肠道通透性及血清内毒素水平增高,微生态制剂枯草杆菌肠球菌二联活菌胶囊可降低肠道通透性、血清内毒素及ALT水平。
Objective To investigate the effect of microecological products capsule containing bacillus subtilis and enterococcus（Medilac-S） on the alteration of intestinal permeability and levels of serum endotoxin in patients with nonalcoholic steatohepatitis（NASH）.Methods Thirty healthy adults and sixty patients with NASH were included in this study.Their serum endotoxin,diamine oxidase,D-lactate and ALT levels were measured respectively.The patients with NASH were treated with Medilac-S for 4 weeks.Results Compared with control,the serum endotoxin,diamine oxidase,and D-lactate levels in patients with NASH increased [143.60±21.41EU/l vs 109.78±17.81EU/l（t=7.71,P0.01）;2.6±0.47U/ml vs 2.3±0.48U/ml（t=2.24,P0.05）;and 6.1±1.05mg/l vs 5.3±0.97mg/l（t=4.89,P0.01）,respectively];after four week treatment with Medilac-S,the serum endotoxin,diamine oxidase,D-lactate and ALT levels decreased remarkably.Conclusions Medilac-S could effectively decrease intestinal permeability and levels of serum endotoxin and ALT in patients with NASH.
出处
《实用肝脏病杂志》
CAS
2012年第2期101-103,共3页
Journal of Practical Hepatology
